Idelalisib

CHEMBL2216870 Phase 4 Disetujui Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

415.4 g/mol

LogP

3.7

Phase

4

This oral targeted therapy inhibits phosphoinositide 3-kinase delta (PI3Kδ), an enzyme involved in the survival, proliferation, and migration of malignant B-cells. It is used to treat relapsed chronic lymphocytic leukemia (CLL) and follicular lymphoma. Serious side effects including liver toxicity, diarrhea, pneumonia, and infections require close monitoring.

Berat Molekul

415,4000 g/mol

LogP

3,70

TPSA

99,20 Å²

Lipinski RO5

Lulus

Area Terapeutik

Pancreatic Cancer Lymphoma Breast Cancer Prostate Cancer Colorectal Cancer Leukemia

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Struktur 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1

InChI

InChI=1S/C22H18FN7O/c1-2-15(28-20-18-19(25-11-24-18)26-12-27-20)21-29-16-10-6-9-14(23)17(16)22(31)30(21)13-7-4-3-5-8-13/h3-12,15H,2H2,1H3,(H2,24,25,26,27,28)/t15-/m0/s1

Molecular Formula

C22H18FN7O

HBD / HBA

2 / 7

Ikatan yang Dapat Dirotasi

5

Atom Berat

31

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Pertanyaan yang Sering Diajukan

This oral targeted therapy inhibits phosphoinositide 3-kinase delta (PI3Kδ), an enzyme involved in the survival, proliferation, and migration of malignant B-cells. It is used to treat relapsed chronic lymphocytic leukemia (CLL) and follicular lymphoma. Serious side effects including liver toxicity, diarrhea, pneumonia, and infections require close monitoring.

Yes, Idelalisib is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2216870. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 11625818. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Mencari informasi yang ramah bagi pasien?

Idelalisib di PillFYI

Struktur

Data Cepat

Rumus: C22H18FN7O
Sinonim: 1

Tautan Eksternal

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Penyangkalan Medis

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.